Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2017

View Archived Issues

Regen Biopharma enters agreement to optimize NR2F6 modulators

Hope Biosciences gains rights to MERTK/AXL inhibitor from NeoPharm

Biogen completes separation of global hemophilia business and launches Bioverativ

FDA orphan drug status given to CyTIX-DCf 12-GLI for malignant glioma

Increased potency of CB-2679d may allow subcutaneous dosing for hemophilia B

FDA grants accelerated approval to Opdivo in metastatic urothelial carcinoma

FDA grants authorization for Abbott RealTime ZIKA test to detect Zika virus using whole blood

Vividion Therapeutics launches with novel drug discovery platform

Protagen and NCI collaborate to provide insight into immuno-oncology

Repatha cardiovascular outcomes study and cognition function study meet primary endpoints

Summit Therapeutics outlines phase III program for ridinilazole

Fortress Biotech's Mustang Bio closes private placement financing to support immunotherapy pipeline

Sustained factor IX activity seen with single infusion of SPK-9001 gene therapy

Galapagos begins dosing patients with cystic fibrosis in ALBATROSS study

GenomeDx to perform genomic tumor profiling for Astellas' ENACT study of enzalutamide

Aviragen reports topline data from phase IIa study of BTA-585 for RSV

Soligenix's SGX-301 granted PIM designation in U.K.

FDA gives orphan drug designation to Lysogene's gene therapy candidate for GM1 gangliosidosis

Glecaprevir/pibrentasvir NDA granted priority review by FDA

Guangzhou Maxinovel Pharmaceuticals divulges novel tyrosine kinase inhibitors

Sunshine Lake Pharma patents orexin receptor antagonists

Bayer discloses new mutant IDH1 inhibitors

Ono Pharmaceutical discovers prostanoid EP2 receptor agonists

Astellas Pharma offers overview of third quarter of fiscal 2016

Pharmakea presents novel lysyl oxidase homolog 2 inhibitors

Daiichi Sankyo reports key milestones of third quarter of fiscal 2016

Promising MOD-5014 results in a phase I/IIa clinical trial in hemophilia patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...